<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William V Bobo, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard C Shelton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H36032236"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bipolar disorder is marked by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>) and nearly always includes episodes of major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Observational studies consistently show that depressive episodes predominate the clinical course of bipolar disorder [<a href="#rid2">2,3</a>]. Compared with manic and hypomanic episodes, bipolar depressive episodes and residual bipolar depressive symptoms account for a greater proportion of long-term morbidity, impaired functioning, and risk of suicide [<a href="#rid4">4,5</a>].</p><p>As a result, improved treatment of major depression is a patient priority. An internet based survey from 11 countries, which asked patients with bipolar disorder (n = 1300) which aspects of care they would most like to see improved, better treatment of depression was endorsed by the largest number (&gt;40 percent) [<a href="#rid6">6</a>]. The second and third leading aspects of care that patients would most like to see improved were avoiding weight gain and preventing relapse of depressive episodes.</p><p>This topic reviews the efficacy, safety, and tolerability of second-generation antipsychotics for bipolar major depression. Other topics discuss choosing treatment for adults with bipolar major depression, the general principles of treating bipolar major depression in adults, the efficacy and adverse effects of antidepressants for bipolar major depression in adults, investigational approaches to treating bipolar major depression in adults, choosing pharmacotherapy for adults with acute mania and hypomania, choosing maintenance treatment for adults, and choosing pharmacotherapy for pediatric bipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115481.html" rel="external">"Bipolar major depression in adults: Investigational and nonstandard approaches to treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p></p><p class="headingAnchor" id="H1837115"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid7">7</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H36032348"><span class="h1">EFFICACY</span><span class="headingEndMark"> — </span>For outpatients with bipolar major depression and no comorbid substance use disorders, randomized trials have established the efficacy of <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">cariprazine</a>, <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a>, <a class="drug drug_general" data-topicid="126411" href="/z/d/drug information/126411.html" rel="external">lumateperone</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, and <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> [<a href="#rid8">8-16</a>]. By contrast, multiple trials have found no benefit in using <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> and <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a> [<a href="#rid17">17,18</a>]. Other second-generation antipsychotics including <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">asenapine</a>, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, and <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> may be helpful, but their benefit has yet to be established. (See <a class="local">'Other second-generation antipsychotics'</a> below.)</p><p>In addition, second-generation antipsychotics are often used as monotherapy or in combination with other drugs for mania, as well maintenance treatment of patients with bipolar disorder. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="headingAnchor" id="H7300681"><span class="h2">Quetiapine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">Quetiapine</a> monotherapy is efficacious for bipolar I or II major depression, based upon multiple meta-analyses of randomized trials that compared quetiapine with placebo [<a href="#rid8">8,19-22</a>]. As an example, one meta-analysis of five trials (3057 patients treated for eight weeks) compared quetiapine with placebo and found that [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Remission occurred in more patients who received <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> than placebo (odds ratio 2.0, 95% CI 1.7-2.3; 61 versus 42 percent of patients)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of anxiety symptoms was greater with <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remission was comparable for <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> 300 mg per day and 600 mg per day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in quality of life (satisfaction) was superior with <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> than placebo</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remission rates were lower for patients with more severe depressive episodes</p><p></p><p>A subsequent eight-week randomized trial in patients with bipolar I or II major depression also found that <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> 300 mg/day was more efficacious than placebo [<a href="#rid23">23</a>].</p><p>In addition, patients with residual symptoms of bipolar major depression may benefit from adjunctive <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>. A six-week randomized trial enrolled patients (n = 32) with bipolar I or II disorder who continued to suffer subsyndromal symptoms of depression and/or hypomania, despite ongoing treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, and/or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid24">24</a>]. Patients were randomly assigned to add-on treatment with quetiapine (300 to 600 mg/day) or placebo; improvement of depressive symptoms was greater with quetiapine.</p><p>However, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> may be less helpful for patients with bipolar major depression and comorbid psychopathology. A randomized trial compared quetiapine (mean dose 276 mg/day) with placebo as monotherapy or add-on treatment in patients with bipolar I or II major depression (n = 100) [<a href="#rid25">25</a>]. Each patient had comorbid generalized anxiety disorder, and most patients had at least one other comorbid psychiatric disorder. Improvement of depressive symptoms with quetiapine and placebo was comparable.</p><p><a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">Quetiapine</a> can cause several adverse effects. Two meta-analyses of five randomized trials (n = 3057) both found that discontinuation of treatment because of side effects occurred in more patients who received quetiapine than placebo (24 versus 6 percent) and was greater for quetiapine 600 mg per day than 300 mg per day [<a href="#rid8">8,10</a>]. Adverse effects that occurred more often with quetiapine than placebo included:</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation</p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea</p><p class="bulletIndent1"><span class="glyph">●</span>Constipation</p><p class="bulletIndent1"><span class="glyph">●</span>Extrapyramidal symptoms</p><p></p><p>Additional information about <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> side effects  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a>.)</p><p>The use of <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> for maintenance treatment of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Quetiapine'</a>.)</p><p class="headingAnchor" id="H7300807"><span class="h3">Bipolar II major depression</span><span class="headingEndMark"> — </span>Randomized trials for bipolar disorder often exclude patients with bipolar II disorder or combine them with bipolar I patients in the analyses. However, several trials of <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> monotherapy included bipolar II patients with major depression and found that the drug was effective for this subgroup:</p><p class="bulletIndent1"><span class="glyph">●</span>Two randomized trials, each lasting eight weeks, compared <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (300 or 600 mg at bedtime) with placebo in patients with bipolar major depression [<a href="#rid26">26</a>]. A pooled analysis of the subgroup of 321 patients with bipolar II depression found that remission was greater with quetiapine 300 or 600 mg/day, compared with placebo (39 and 38 versus 20 percent). This was consistent with the finding that both doses of quetiapine were superior in the total sample of bipolar patients [<a href="#rid27">27</a>]. Among patients with bipolar II depression, discontinuation of treatment due to adverse effects of quetiapine 300 mg/day and 600 mg/day and placebo were 16, 23, and 2 percent; common side effects of quetiapine included dry mouth, sedation, fatigue, and dizziness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week randomized trial compared <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (300 or 600 mg at bedtime) with placebo in patients with bipolar major depression [<a href="#rid28">28</a>]. In the subgroup of 208 patients with bipolar II disorder, symptoms improved more with both doses of quetiapine than placebo; this was consistent with the finding that quetiapine was superior in patients with bipolar I disorder.</p><p></p><p class="headingAnchor" id="H86357398"><span class="h3">Compared with other drugs</span><span class="headingEndMark"> — </span>Although head-to-head randomized trials seem to suggest that <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> monotherapy is superior to <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> monotherapy or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> monotherapy for bipolar major depression, the comparative benefit of quetiapine is not clear due to methodologic problems:</p><p class="bulletIndent1"><span class="glyph">●</span>One eight-week trial assigned patients to <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> 300 mg per day (n = 255), quetiapine 600 mg per day (n = 263), or <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> (target serum concentration 0.6 to 1.2 mEq/L [0.6 to 1.2 mmol/L]; n = 136) [<a href="#rid29">29</a>]. Although symptoms improved more with either dose of quetiapine than with lithium, the study was underpowered for lithium [<a href="#rid30">30</a>]. In addition, the mean serum concentration of lithium was 0.61 mEq/L (0.61 mmol/L), and more than a third of the patients treated with lithium had a median serum concentration &lt;0.6 mEq/L (&lt;0.6 mmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One eight-week trial assigned patients to <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> 300 mg per day (n = 229), quetiapine 600 mg per day (n = 232), or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> 20 mg per day (n = 118) [<a href="#rid28">28</a>]. Although symptoms improved more with either dose of quetiapine than with paroxetine, the study was underpowered for paroxetine. In addition, the paroxetine dose was at the low end of the dose range that is usually used to treat major depression  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 5</a>).</p><p></p><p class="headingAnchor" id="H173197880"><span class="h2">Olanzapine</span><span class="headingEndMark"> — </span>For patients with bipolar major depression, randomized trials have demonstrated the efficacy of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> monotherapy [<a href="#rid20">20,21,31</a>]. Clinicians can anticipate that among patients treated with olanzapine, approximately 35 percent will remit:</p><p class="bulletIndent1"><span class="glyph">●</span>One six-week trial compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (5 to 20 mg per day) with placebo in 514 patients; use of concomitant medication was not reported. Remission occurred in more patients who received olanzapine than placebo (38 versus 29 percent), and discontinuation of treatment due to adverse effects was comparable (9 and 8 percent) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One eight-week trial compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (5 to 20 mg per day) with placebo in 706 patients; benzodiazepines and anticholinergic drugs were allowed as well. Remission occurred in more patients who received olanzapine than placebo (33 versus 25 percent) [<a href="#rid9">9</a>]. However, discontinuation of treatment due to adverse effects occurred in more patients who received olanzapine than placebo (9 versus 5 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another eight-week trial compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (mean dose 14 mg per day) with placebo in 68 patients; hypnotic and anticholinergic drugs were allowed as well [<a href="#rid32">32</a>]. Remission occurred in more patients who received olanzapine than placebo (35 versus 12 percent).</p><p></p><p>Subgroup analyses have found that in bipolar major depression with mixed features [<a href="#rid33">33</a>] and bipolar major depression with anxiety symptoms [<a href="#rid9">9</a>], <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> is more effective than placebo.</p><p>In addition, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> may improve sleep disturbances. A small, four-week randomized trial compared add-on olanzapine (5 to 10 m/day) with placebo in patients with bipolar major depression (n = 25) and assessed patients with home-based sleep recordings; sleep continuity and architecture improved more with olanzapine [<a href="#rid34">34</a>].</p><p><a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a> can cause serious weight gain and may also cause diabetes mellitus [<a href="#rid35">35-37</a>]. In randomized trials that compared olanzapine with placebo in patients with bipolar major depression, the following adverse effects occurred more often with olanzapine [<a href="#rid9">9,11,32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation</p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain</p><p class="bulletIndent1"><span class="glyph">●</span>Increased appetite</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercholesterolemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertriglyceridemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Alanine aminotransferase abnormally high</p><p class="bulletIndent1"><span class="glyph">●</span>Aspartate aminotransferase abnormally high</p><p class="bulletIndent1"><span class="glyph">●</span>Gamma glutamyl transpeptidase abnormally high</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperprolactinemia</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia</p><p></p><p>Additional information about <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> side effects  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a>.)</p><p>Use of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> is limited due to side effects, particularly weight gain and metabolic disease. Although a 12-week randomized trial in patients with schizophrenia found that combining samidorphan with olanzapine can mitigate the weight gain that occurs with olanzapine monotherapy [<a href="#rid38">38</a>], a subsequent 24-week trial found that in nearly 30 percent of patients, the combination caused weight gain ≥7 percent of baseline weight [<a href="#rid39">39</a>]. (Weight change ≥7 percent is regarded as clinically significant.) Patients who completed the 24-week trial were enrolled in a 52-week prospective observational study, which found that weight gain ≥7 percent or weight loss ≥7 percent each occurred in approximately 21 percent of patients who received olanzapine plus samidorphan [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H173197887"><span class="h3">Olanzapine plus fluoxetine</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> for bipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Acute treatment'</a>.)</p><p class="headingAnchor" id="H357179"><span class="h2">Lurasidone</span><span class="headingEndMark"> — </span>For bipolar I major depression, one randomized trial found that <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> monotherapy can be efficacious, and a second trial found that lurasidone can be efficacious as add-on treatment with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>. However, a third trial found that add-on lurasidone was not beneficial [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lurasidone</strong><strong> monotherapy </strong>– A six-week trial randomly assigned 505 patients to receive <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> 20 to 60 mg per day, lurasidone 80 to 120 mg per day, or placebo [<a href="#rid12">12</a>]. Improvement of symptoms and functional impairment was greater with each lurasidone group than placebo, and the benefit of the two lurasidone dose ranges was similar. As an example, remission was greater with low dose and high dose lurasidone, compared with placebo (42 and 40 versus 25 percent of patients). Lurasidone was also efficacious in the subgroup of patients with bipolar I major depression with mixed features [<a href="#rid42">42</a>]. In addition, discontinuation of treatment due to adverse effects was similar for the three treatment groups (approximately 6 to 7 percent of patients within each group).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lurasidone</strong><strong> add-on therapy </strong>– A six-week trial enrolled 348 patients who had not adequately responded to at least one month of treatment with either <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> monotherapy or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> monotherapy, and randomly assigned them to adjunctive treatment with <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> (20 to 120 mg per day) or placebo [<a href="#rid13">13</a>]. Remission occurred in more patients who received add-on lurasidone than placebo (50 versus 35 percent). In addition, improvement of functioning was greater with lurasidone. Discontinuation of treatment due to adverse effects was comparable for lurasidone and placebo (6 and 8 percent of patients).</p><p></p><p class="bulletIndent1">However, a second six-week trial (n = 356 patients), using the same methods to compare augmentation with either <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> or placebo, found that remission for the two groups was comparable (34 and 28 percent) [<a href="#rid41">41,43</a>].</p><p></p><p>A prospective, observational study enrolled patients who completed the three randomized trials and followed them for six months, during which all patients (n = 817) received open label treatment with <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> (20 to 120 mg/day) [<a href="#rid44">44</a>]. On average, patients showed further improvement of depressive symptoms.</p><p>In the three randomized trials, the most frequently reported side effects of <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> were [<a href="#rid12">12,13,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Akathisia</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Insomnia</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation</p><p class="bulletIndent1"><span class="glyph">●</span>Extrapyramidal</p><p></p><p>Based upon our clinical experience, administering <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> with food (eg, &gt;350 kilocalories) may limit gastrointestinal side effects. Additional information about lurasidone side effects are shown in the table  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H1580868972"><span class="h2">Cariprazine</span><span class="headingEndMark"> — </span>Based upon three randomized trials, each lasting six weeks, <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">cariprazine</a> is efficacious for patients with bipolar I major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>One trial (n = 571 patients) compared <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">cariprazine</a> (0.75, 1.5, or 3 mg/day) with placebo [<a href="#rid14">14</a>]. Across multiple outcomes, cariprazine 1.5 mg/day was superior to placebo; as an example, remission occurred in more patients who received cariprazine 1.5 mg/day than placebo (30 versus 16 percent). Cariprazine 3 mg/day was more efficacious than placebo on some outcomes, but not others. Cariprazine 0.75 mg/day provided little advantage over placebo. Discontinuation of treatment due to adverse events was comparable for the four groups. Akathisia was the most common adverse effect of cariprazine, and occurred in a dose-dependent fashion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second trial (n = 480 patients) compared <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">cariprazine</a> (1.5 or 3 mg/day) with placebo [<a href="#rid15">15</a>]. Remission occurred in more patients treated with cariprazine 1.5 or 3 mg/day than placebo (33 and 32 versus 23 percent). Discontinuation of treatment due to adverse effects appeared to be comparable in patients who received cariprazine 1.5 mg/day, 3 mg/day, and placebo (4, 5, and 3 percent). Adverse effects that occurred in at least 5 percent of patients in either cariprazine group, and in at least twice as many patients receiving placebo, were akathisia, dizziness, nausea, and sedation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third trial (n = 493) also compared <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">cariprazine</a> (1.5 or 3 mg/day) with placebo [<a href="#rid45">45</a>]. Cariprazine 1.5 mg/day was more efficacious than placebo on some outcomes, but not others. Cariprazine 3 mg/day provided little to no advantage over placebo. Among patients treated with cariprazine 1.5 mg/day, 3 mg/day, or placebo, discontinuation of treatment due to adverse effects occurred in 3, 7, and 3 percent of patients. Adverse effects that occurred in at least 5 percent of patients in either cariprazine group, and at least twice the rate as placebo, were akathisia/restlessness, fatigue, and nausea.</p><p></p><p class="headingAnchor" id="H369045170"><span class="h2">Lumateperone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126411" href="/z/d/drug information/126411.html" rel="external">Lumateperone</a> appears to be effective in the treatment of acute major depression in the context of either bipolar I or bipolar II disorder. Lumateperone is a novel antipsychotic that modulates serotonin, dopamine, and glutamate neurotransmission that is approved in the United States for the treatment of schizophrenia. It has been US Food and Drug Administration-approved for major depressive episodes in both bipolar I and II disorder, making it the only medication to have indications for both disorders. In one trial, 377 individuals with an acute episode of major depression in the context of bipolar disorder were randomized to receive six weeks of lumateperone 42 mg/day versus placebo [<a href="#rid16">16</a>]. Lumateperone was associated with greater reduction on the Montgomery Asberg Depression Rating Scale (MADRS), a 60-point clinician rating scale for depression (mean change -16.7; mean difference with placebo 4.6, 95% CI -6.34 to -2.83). Additionally, response rates (defined as &gt;50 percent decline in MADRS) and remission rates (MADRS &lt;12) favored lumateperone over placebo (51 versus 37 percent and 40 versus 34 percent, respectively). Of note, improvements in MADRS scores compared with placebo were noted for both individuals with bipolar I and bipolar II disorder. Furthermore, treatment emergent side effects such as extrapyramidal symptoms, metabolic dysregulation, and weight gain were minimal and similar to placebo. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H5519998"><span class="h2">Other second-generation antipsychotics</span><span class="headingEndMark"> — </span>Low quality evidence (eg, indirect outcome, lack of placebo or other control, or small sample), as well as unpublished studies, suggests that monotherapy with other second-generation antipsychotics may possibly be useful for treating bipolar major depression [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asenapine</strong> – A pooled analysis of two randomized trials, each lasting three weeks, compared <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">asenapine</a> (5 or 10 mg twice per day) with placebo in a subgroup of 173 patients with major depression concurrent with mania [<a href="#rid47">47</a>]. Remission occurred in more patients treated with asenapine than placebo (45 versus 24 percent); this was consistent with the finding that asenapine was superior in the total sample of patients with mania. However, among patients with concurrent depression and mania, sedation, dizziness, extrapyramidal symptoms, and weight gain occurred more often with asenapine than placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clozapine</strong> – A retrospective observational study of 326 patients treated with adjunctive <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> (mean dose 307 mg per day) for up to two years found that the number of hospitalizations and number of days in the hospital were lower during clozapine treatment than the same period of time immediately prior to use of clozapine [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risperidone</strong> – One trial enrolled 30 patients with an incomplete response to <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and randomly assigned the patients to receive adjunctive <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, or risperidone plus paroxetine [<a href="#rid49">49</a>]. All three groups improved.</p><p></p><p>The side effects  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>) of these drugs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H36032278"><span class="h2">Drugs with little to no benefit</span><span class="headingEndMark"> — </span>For patients with bipolar major depression, multiple randomized trials indicate that there is little to no benefit in using <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> or <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aripiprazole</strong> – Two eight-week trials compared <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> (5 to 30 mg per day) with placebo in a total of 749 patients; a meta-analysis and a pooled analysis each found that the benefits of aripiprazole and placebo were comparable [<a href="#rid17">17,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ziprasidone</strong> – Two six-week trials compared <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a> (20 to 80 mg twice daily) with placebo in a total of 856 patients; in each trial, ziprasidone demonstrated no advantage [<a href="#rid18">18,20,50</a>]</p><p></p><p class="headingAnchor" id="H36032292"><span class="h2">Rapid cycling bipolar disorder</span><span class="headingEndMark"> — </span>The efficacy of second-generation antipsychotics to treat bipolar major depression in rapid cycling patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2229622"><span class="h2">Geriatric bipolar disorder</span><span class="headingEndMark"> — </span>The efficacy of second-generation antipsychotics to treat bipolar major depression in geriatric patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line treatment'</a>.)</p><p class="headingAnchor" id="H36032356"><span class="h1">SAFETY AND TOLERABILITY</span></p><p class="headingAnchor" id="H259519902"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Side effects associated with second-generation antipsychotics include weight gain, hyperglycemia, type 2 diabetes mellitus, hyperlipidemia, sedation, hyperprolactinemia, neuroleptic malignant syndrome, orthostatic hypotension, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in older adult patients  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>). Second-generation antipsychotics can also cause extrapyramidal symptoms and tardive dyskinesia, but at rates lower than first-generation drugs. These side effects and their management are described separately. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4908.html" rel="external">"Tardive dyskinesia: Prevention, treatment, and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'</a>.)</p><p>General principles regarding the safety and tolerability of second-generation antipsychotics in bipolar major depression include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with bipolar depression may be more sensitive to side effects than patients with mania [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of extrapyramidal side effects and tardive dyskinesia is thought to be higher in bipolar disorder than schizophrenia [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment-emergent mania does not occur in patients who are treated with <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> [<a href="#rid9">9-11,55</a>].</p><p></p><p>In addition, adverse effects can lead to poor adherence [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H259517724"><span class="h3">Metabolic effects</span><span class="headingEndMark"> — </span>The risk of metabolic side effects (eg, weight gain, hyperlipidemia, and hyperglycemia) is increased with some second-generation antipsychotics [<a href="#rid57">57</a>]; this is important given the increased risk of metabolic syndrome [<a href="#rid58">58</a>] as well as cardiovascular morbidity and mortality in patients with bipolar disorder relative to the general population [<a href="#rid59">59-61</a>]. Although most studies of second-generation antipsychotics and metabolic effects involve schizophrenia [<a href="#rid57">57</a>], comparable effects have been found in bipolar disorder [<a href="#rid8">8,55,62,63</a>]. Among second-generation antipsychotics, the greatest risk for metabolic effects is with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, followed by <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> and <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>) [<a href="#rid64">64</a>]. The risk of clinically significant weight gain for olanzapine monotherapy and olanzapine plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> appears to be comparable [<a href="#rid9">9,65</a>]. A review found that in short-term (≤12 weeks) randomized trials, <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">asenapine</a> also causes weight gain, whereas <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a> does not [<a href="#rid66">66</a>].</p><p>Prior to initiating treatment with second-generation antipsychotics, we ask patients about their personal and family history of obesity, diabetes, dyslipidemia, hypertension, cardiovascular disease, and family history of sudden cardiac death [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H259518705"><span class="h3">Sedation</span><span class="headingEndMark"> — </span>Among patients with bipolar major depression, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> often cause somnolence that leads to discontinuation of treatment [<a href="#rid52">52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an eight-week randomized trial that compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> with placebo in 706 patients, discontinuation of treatment due to adverse effects occurred in more patients treated with olanzapine than placebo (9 versus 5 percent) [<a href="#rid9">9</a>]. Among patients who discontinued olanzapine because of side effects, the most frequent cause was sedation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five randomized trials (2477 patients treated for eight weeks) that compared <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> with placebo found that discontinuation of treatment due to somnolence was nearly five times more likely in patients who received quetiapine [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H173197509"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Bipolar patients who are treated with second-generation antipsychotics should be assessed for [<a href="#rid64">64,67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic side effects at baseline and periodically thereafter  (<a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extrapyramidal symptoms at baseline and subsequently at every visit. Patients should also be monitored for tardive dyskinesia at baseline, quarterly in the first year, and annually thereafter, using the Abnormal Involuntary Movement Scale  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orthostatic hypotension at baseline and periodically thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolactin elevation at baseline and periodically thereafter.</p><p></p><p>In addition, patients may need to be monitored for QT prolongation. Additional information about assessing patients for metabolic side effects, extrapyramidal symptoms, orthostasis, hyperprolactinemia, and QT prolongation is discussed further in the context of schizophrenia. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'</a>.)</p><p class="headingAnchor" id="H36032399"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of bipolar depression</strong> – Depressive episodes predominate the clinical course of bipolar disorder. They account for a greater proportion of long-term morbidity, greater impairment in functioning, and a higher risk of suicide than mania or hypomanic episodes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment selection </strong>– We choose medication regimens for bipolar disorder according to the phase of the illness. Side effect profiles, patient comorbidity, and drug-drug interactions are also considered. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a> and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and tolerability </strong>–<strong> </strong>Trials investigating the efficacy of specific agents in the treatment of bipolar major depression have shown the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Quetiapine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">Quetiapine</a> monotherapy is efficacious for short-term treatment of bipolar I or bipolar II major depression. However, side effects such as sedation, weight gain, dry mouth, constipation, extrapyramidal symptoms and QTc prolongation may lead to discontinuation. (See <a class="local">'Quetiapine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Olanzapine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a> monotherapy may be efficacious for short-term treatment of bipolar I major depression and appears to be effective for bipolar depression with mixed features. However, side effects such as sedation, weight gain, metabolic dysregulation, hyperprolactinemia, neutropenia, elevated liver functions, and diabetes mellitus may limit its use. (See <a class="local">'Olanzapine'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Olanzapine</strong><strong> plus </strong><strong>fluoxetine</strong> – The combination is widely studied and is efficacious for short-term treatment of bipolar I major depression. (See <a class="local">'Olanzapine'</a> above and  <a class="medical medical_review" href="/z/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lurasidone</strong><strong> </strong>– <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">Lurasidone</a> is efficacious as monotherapy in the treatment of bipolar I disorder and bipolar I disorder with mixed features. Lurasidone may also be efficacious as add-on therapy with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> for bipolar I major depression. Side effects include akathisia, headache, insomnia, nausea, sedation, tremor, and extrapyramidal symptoms. (See <a class="local">'Lurasidone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cariprazine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">Cariprazine</a> is efficacious in the treatment of bipolar I major depression. Side effects include weight gain, sedation, and akathisia. (See <a class="local">'Cariprazine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lumateperone</strong><strong> </strong>– <a class="drug drug_general" data-topicid="126411" href="/z/d/drug information/126411.html" rel="external">Lumateperone</a> appears to be effective in the treatment of acute major depression in the context of bipolar I or bipolar II disorder. Lumateperone appears to have minimal treatment emergent side effects. (See <a class="local">'Lumateperone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other second-generation antipsychotics</strong> – Low-quality evidence or unpublished studies suggest that monotherapy with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, or <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">asenapine</a> may be useful for treating bipolar I major depression. (See <a class="local">'Other second-generation antipsychotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drugs with no benefit</strong> – Multiple randomized trials indicate no benefit for either <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> or <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>. (See <a class="local">'Drugs with little to no benefit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common adverse effects </strong>– Side effects associated with second-generation antipsychotics include weight gain, hyperglycemia, type 2 diabetes mellitus, hyperlipidemia, sedation, hyperprolactinemia, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, orthostatic hypotension, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in older adult patients. Additionally, some agents may cause QTc prolongation. Side effects of specific antipsychotics are discussed above and elsewhere  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 4</a>). (See <a class="local">'Side effects'</a> above and  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– We monitor individuals treated with second generation antipsychotics for bipolar disorder for metabolic side effects  (<a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">table 6</a>), extrapyramidal symptoms, tardive dyskinesia  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>), and orthostatic hypotension on a regular basis. We obtain an electrocardiogram prior to starting medication and at regular intervals in all individuals at risk for prolonged QTc or treated with medications with high propensity to cause prolonged QTc. (See <a class="local">'Monitoring'</a> above and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.</a></li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.</a></li><li><a class="nounderline abstract_t">Simon GE, Bauer MS, Ludman EJ, et al. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007; 68:1237.</a></li><li><a class="nounderline abstract_t">Rihmer Z. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2005; 2:48.</a></li><li><a class="nounderline abstract_t">McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009; 70 Suppl 3:5.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012; 26:603.</a></li><li><a class="nounderline abstract_t">Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.</a></li><li><a class="nounderline abstract_t">Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012; 27:76.</a></li><li><a class="nounderline abstract_t">Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012; 201:376.</a></li><li><a class="nounderline abstract_t">Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:160.</a></li><li><a class="nounderline abstract_t">Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171:169.</a></li><li><a class="nounderline abstract_t">Durgam S, Earley W, Lipschitz A, et al. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry 2016; 173:271.</a></li><li><a class="nounderline abstract_t">Earley W, Burgess MV, Rekeda L, et al. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry 2019; 176:439.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Durgam S, Satlin A, et al. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. Am J Psychiatry 2021; 178:1098.</a></li><li><a class="nounderline abstract_t">Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28:13.</a></li><li><a class="nounderline abstract_t">Lombardo I, Sachs G, Kolluri S, et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012; 32:470.</a></li><li><a class="nounderline abstract_t">Vieta E, Locklear J, Günther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010; 30:579.</a></li><li><a class="nounderline abstract_t">Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014; 47:43.</a></li><li><a class="nounderline abstract_t">Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand 2014; 130:452.</a></li><li><a class="nounderline abstract_t">Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther 2014; 8:827.</a></li><li><a class="nounderline abstract_t">Li H, Gu N, Zhang H, et al. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2016; 233:1289.</a></li><li><a class="nounderline abstract_t">Garriga M, Solé E, González-Pinto A, et al. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial. Eur Neuropsychopharmacol 2017; 27:959.</a></li><li><a class="nounderline abstract_t">Gao K, Wu R, Kemp DE, et al. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75:1062.</a></li><li><a class="nounderline abstract_t">Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9:198.</a></li><li><a class="nounderline abstract_t">Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69:769.</a></li><li><a class="nounderline abstract_t">McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.</a></li><li><a class="nounderline abstract_t">Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.</a></li><li><a class="nounderline abstract_t">Grunze HC. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression. Evid Based Ment Health 2010; 13:88.</a></li><li><a class="nounderline abstract_t">Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013; 149:196.</a></li><li><a class="nounderline abstract_t">Wang M, Tong JH, Huang DS, et al. Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study. Psychopharmacology (Berl) 2014; 231:2811.</a></li><li><a class="nounderline abstract_t">Tohen M, Kanba S, McIntyre RS, et al. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord 2014; 164:57.</a></li><li><a class="nounderline abstract_t">Monti JM. The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder. Sleep Med 2016; 23:89.</a></li><li><a class="nounderline abstract_t">Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.</a></li><li><a class="nounderline abstract_t">Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31:154.</a></li><li><a class="nounderline abstract_t">Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.</a></li><li><a class="nounderline abstract_t">Martin WF, Correll CU, Weiden PJ, et al. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. Am J Psychiatry 2019; 176:457.</a></li><li><a class="nounderline abstract_t">Correll CU, Newcomer JW, Silverman B, et al. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Am J Psychiatry 2020; 177:1168.</a></li><li><a class="nounderline abstract_t">Kahn RS, Silverman BL, DiPetrillo L, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. Schizophr Res 2021; 232:45.</a></li><li><a class="nounderline abstract_t">Sanford M, Dhillon S. Lurasidone: a review of its use in adult patients with bipolar I depression. CNS Drugs 2015; 29:253.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015; 76:398.</a></li><li><a class="nounderline abstract_t">Suppes T, Calabrese JR, Silva R, et al. Lurasidone adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study (poster abstract W147). Neuropsychopharmacology 2013; 38 (Suppl 2s):S533.</a></li><li><a class="nounderline abstract_t">Ketter TA, Sarma K, Silva R, et al. LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depress Anxiety 2016; 33:424.</a></li><li><a class="nounderline abstract_t">Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020; 22:372.</a></li><li><a class="nounderline abstract_t">Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 2015; 17:235.</a></li><li><a class="nounderline abstract_t">Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013; 145:62.</a></li><li><a class="nounderline abstract_t">Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14:863.</a></li><li><a class="nounderline abstract_t">Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65:1715.</a></li><li><a class="nounderline abstract_t">Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:1413.</a></li><li><a class="nounderline abstract_t">Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14:131.</a></li><li><a class="nounderline abstract_t">Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008; 69:302.</a></li><li><a class="nounderline abstract_t">Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl 4:33.</a></li><li><a class="nounderline abstract_t">Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28:203.</a></li><li><a class="nounderline abstract_t">Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7:40.</a></li><li><a class="nounderline abstract_t">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.</a></li><li><a class="nounderline abstract_t">Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170:265.</a></li><li><a class="nounderline abstract_t">Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry 2011; 23:40.</a></li><li><a class="nounderline abstract_t">Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11:657.</a></li><li><a class="nounderline abstract_t">Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844.</a></li><li><a class="nounderline abstract_t">Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118:4.</a></li><li><a class="nounderline abstract_t">Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011; 72:1063.</a></li><li><a class="nounderline abstract_t">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.</a></li><li><a class="nounderline abstract_t">Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009; 29:358.</a></li><li><a class="nounderline abstract_t">De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012; 26:733.</a></li><li><a class="nounderline abstract_t">Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334.</a></li></ol></div><div id="topicVersionRevision">Topic 16693 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044195" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The long-term natural history of the weekly symptomatic status of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854249" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prediction and prevention of suicide in bipolar disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570496" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570496" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940761" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609883" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22107783" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Quetiapine for bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918966" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170180" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170221" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26541814" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30845817" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551584" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204335" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722504" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20814319" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment options for bipolar depression: a systematic review of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549862" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25283309" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25028535" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Quetiapine for acute bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911380" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28882405" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25007003" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17853277" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452345" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122366" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122369" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682828" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23485111" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481570" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24856554" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692282" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337666" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346617" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Metabolic effects of olanzapine in patients with newly diagnosed psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20838345" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiovascular aspects of antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30845818" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32791894" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34015555" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25698146" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lurasidone: a review of its use in adult patients with bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25844756" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lurasidone adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study (poster abstract W147)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26918425" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31628698" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25346322" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clozapine for treatment-resistant bipolar disorder: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22868059" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23107278" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641878" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risperidone and paroxetine given singly and in combination for bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21672493" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20875219" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18211129" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739329" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344731" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17705840" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adherence to medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998156" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361837" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21318195" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cardiovascular morbidity and mortality in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689508" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545667" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Excess mortality in bipolar and unipolar disorder in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18498432" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21034695" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747245" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593175" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22900950" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15285957" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Physical health monitoring of patients with schizophrenia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
